Cort-Donmez, AysegulOlgen, SureyyaGuner, ErsinAkgun-Cagliyan, GulsumHanikoglu, FerhatTunc-Ata, MelekKilic-Toprak, Emine2026-01-242026-01-2420231871-52061875-5992https://doi.org/10.2174/1871520622666220513114205https://hdl.handle.net/20.500.12868/5291Background Src family tyrosine kinases play a potential role in Bcr-Abl-induced leukemogenesis. Src kinase inhibitors are reported as selective inhibitors of chronic myeloid leukemia. Objective Since Src kinase inhibitors have an inhibitive effect on chronic myeloid leukemia, indole derivatives (C-1, C-2, C-3) previously found as potent inhibitors of Src kinase were tested against chronic myeloid leukemia in this study. Methods Cell viability of K562 and R/K562 cells, antiproliferative and antioxidant effects, and inhibition profiles of Bcr-Abl kinase of indole derivatives were determined compared to dasatinib and imatinib. Results The results showed that compounds affected cell proliferation and decreased the levels of Bcr/Abl. These results confirmed that the antileukemic activity of compounds was related to Bcr/Abl expression. Docking studies also presented that compounds are inhibitors of both Src and Abl kinases. Calculation of drug-like properties showed that compounds could be potential drug candidates. Conclusion Among indole-2-on derivatives, previously identified as Src kinase inhibitors, C-2 has been discovered to be a strong anticancer drug that is active against susceptible and resistant K562 cell lines and induces apoptosis.eninfo:eu-repo/semantics/closedAccessIndole-2-on derivativesanti-proliferativecell viabilitySrcABldockingArticle10.2174/1871520622666220513114205231113122355705192-s2.0-85144018225Q2WOS:000958469200010Q3